Transaction DateRecipientSharesTypePriceValue
24th February 2020Vimal Mehta300,000Sale back to the issuer$30.08$9,024,000.00
24th February 2020Krishnan Nandabalan300,000Sale back to the issuer$30.08$9,024,000.00
14th February 2020Frank Yocca80,000Exercise of derivative$0.41$32,800.00
23rd August 2019Peter Mueller1,554Open or private purchase$9.34$14,514.36
22nd August 2019Peter Mueller6,646Open or private purchase$8.83$58,684.18
21st August 2019Peter Mueller1,800Open or private purchase$8.42$15,156.00
16th August 2019Vimal Mehta974Open or private purchase$8.89$8,658.86
15th August 2019Vimal Mehta2,625Open or private purchase$8.67$22,758.75
14th August 2019Vimal Mehta358Open or private purchase$8.44$3,021.52
13th August 2019Frank Yocca6,547Open or private purchase$8.67$56,762.49
Bio Xcel Therapeutics
Bio Xcel Therapeutics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.


BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focuses on drug development. The firm's two clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.


Ticker: BTAI
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1720893
Employees: 24
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals